Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568560 | 0.87 | OPRM1 (0.40) | SMN1; SMN2OPRM1EPHX1EPHX2 | |
| SCHEMBL14530950 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2EPHX1EPHX2HSD11B1ACHE | |
| SCHEMBL15314563 | 0.84 | NCF1 (0.39) | OPRM1 | |
| SCHEMBL15998881 | 0.83 | ALOX5 (0.40) | — | |
| SCHEMBL27430620 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2OPRM1EPHX1EPHX2HSD11B1 | |
| SCHEMBL23560054 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2EPHX1EPHX2HSD11B1ACHE | |
| SCHEMBL19652262 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2EPHX1EPHX2HSD11B1ACHE | |
| SCHEMBL10205115 | 0.80 | ACHE (0.33) | OPRM1ACHE | |
| SCHEMBL11892779 | 0.80 | ALOX5 (0.44) | OPRM1 | |
| SCHEMBL19658490 | 0.78 | ACHE (0.63) | OPRM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | SMN1; SMN2 4117/4885OPRM1 4578/4885EPHX1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.